[{"address1": "100 SE 2nd St.", "address2": "Suite 2000 #1009", "city": "Miami", "state": "FL", "zip": "33131", "country": "United States", "phone": "813 864 2558", "website": "https://telomirpharma.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Telomir Pharmaceuticals, Inc., a preclinical stage pharmaceutical company, is engaged in the advancement of age reversal science. The company is developing Telomir 1, a small molecule intended to lengthen and protect telomeres, the DNA end caps of chromosomes that are associated with cellular aging. Telomir 1 is designed for oral administration and is aimed at extending longevity, improving quality of life, and potentially influencing biological aging. Telomir Pharmaceuticals is also involved in ongoing preclinical research into Progeria, diabetes, cancer, Alzheimer's disease, osteoarthritis, and other age related conditions to assess the potential effects of Telomir 1. The company was formerly known as Metallo Therapies Inc. and changed its name to Telomir Pharmaceuticals, Inc. in October 2022. Telomir Pharmaceuticals, Inc. was incorporated in 2021 and is headquartered in Miami, Florida.", "fullTimeEmployees": 1, "companyOfficers": [{"maxAge": 1, "name": "Mr. Erez  Aminov", "age": 46, "title": "Chairman of the Board & CEO", "yearBorn": 1978, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Itzchak  Angel Ph.D.", "title": "Chief Scientific Advisor", "exercisedValue": 0, "unexercisedValue": 0}], "maxAge": 86400, "priceHint": 4, "previousClose": 4.79, "open": 4.83, "dayLow": 4.61, "dayHigh": 4.9417, "regularMarketPreviousClose": 4.79, "regularMarketOpen": 4.83, "regularMarketDayLow": 4.61, "regularMarketDayHigh": 4.9417, "volume": 46656, "regularMarketVolume": 46656, "averageVolume": 183386, "averageVolume10days": 125710, "averageDailyVolume10Day": 125710, "bid": 4.58, "ask": 4.76, "bidSize": 100, "askSize": 100, "marketCap": 139540160, "fiftyTwoWeekLow": 3.11, "fiftyTwoWeekHigh": 20.72, "fiftyDayAverage": 4.5904, "twoHundredDayAverage": 5.22826, "currency": "USD", "enterpriseValue": 138128816, "forwardPE": -20.391304, "floatShares": 17465053, "sharesOutstanding": 29752700, "sharesShort": 1274337, "sharesShortPriorMonth": 650601, "sharesShortPreviousMonthDate": 1732838400, "dateShortInterest": 1735603200, "sharesPercentSharesOut": 0.0428, "heldPercentInsiders": 0.42664, "heldPercentInstitutions": 0.06926, "shortRatio": 3.93, "shortPercentOfFloat": 0.0756, "impliedSharesOutstanding": 29752700, "bookValue": 0.015, "priceToBook": 312.6667, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1727654400, "netIncomeToCommon": -22961558, "trailingEps": -0.77, "52WeekChange": -0.041999996, "SandP52WeekChange": 0.22408533, "exchange": "NCM", "quoteType": "EQUITY", "symbol": "TELO", "underlyingSymbol": "TELO", "shortName": "Telomir Pharmaceuticals, Inc.", "longName": "Telomir Pharmaceuticals, Inc.", "firstTradeDateEpochUtc": 1707489000, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EST", "uuid": "d984ac0c-78a7-3cac-896b-bd86d543ef9b", "messageBoardId": "finmb_1831658436", "gmtOffSetMilliseconds": -18000000, "currentPrice": 4.69, "targetHighPrice": 12.15, "targetLowPrice": 12.15, "targetMeanPrice": 12.15, "targetMedianPrice": 12.15, "recommendationKey": "strong_buy", "numberOfAnalystOpinions": 1, "totalCash": 834638, "totalCashPerShare": 0.028, "totalDebt": 93432, "quickRatio": 1.391, "currentRatio": 1.737, "debtToEquity": 21.135, "returnOnAssets": -2.04686, "returnOnEquity": -17.52693, "freeCashflow": 213647, "operatingCashflow": -5551835, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2025-01-18"}]